12 Most Oversold Healthcare Stocks to Buy Now
Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that healthcare spending in the US reached $4.9 trillion in 2023, up 7.5% from 2022.
Apellis Pharmaceuticals Inc. (APLS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 12,222,222 | $390,011,104 | +10% | 5.51% |
| 2. | EcoR1 Capital Oleg Nodelman | 11,890,843 | $379,436,800 | 14.34% | |
| 3. | Deep Track Capital David Kroin | 4,274,921 | $136,412,729 | -3% | 5.08% |
| 4. | Octagon Capital Advisors Ting Jia | 3,006,980 | $95,952,732 | 15.78% | |
| 5. | Siren L.L.C. Raymond Debbane | 2,816,258 | $89,866,793 | 3.97% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.00 | 250,000 | Large Shareholder | 12,806,342 | 2021-11-18 | Filing | |
| $31.81 | 5,000 | Director | 5,000 | 2020-05-08 | Filing | |
| $37.00 | 540,540 | Large Shareholder | 12,556,342 | 2020-01-13 | Filing | |
| $29.71 | 11,699 | Officer | 11,699 | 2019-08-29 | Filing | |
| $17.00 | 441,176 | Large Shareholder | 12,015,802 | 2019-03-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.54 | 363 | Officer | 83,945 | 2025-02-11 | Filing | |
| $29.52 | 695 | Officer | 144,299 | 2025-01-29 | Filing | |
| $29.52 | 695 | Officer | 84,050 | 2025-01-29 | Filing | |
| $29.52 | 546 | Officer | 128,665 | 2025-01-29 | Filing | |
| $29.52 | 825 | Officer | 83,664 | 2025-01-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,800,849 | $376,565,091 | 0.06% | |
| 2. | 10,046,025 | $320,568,658 | 0% | |
| 3. | 9,627,227 | $307,204,831 | 0.02% | |
| 4. | 6,477,989 | $206,712,639 | 0% | |
| 5. | 4,525,155 | $144,397,696 | 0% |
News See All
10 Top Insider Stock Buys And Sells In January
Ever heard of the “January effect?” In case you haven’t, a “January effect” is considered a phenomenon in the stock market where stock prices, most commonly of small-cap stocks, rise in the ...
10 Mid-Cap Stocks Insiders Are Selling Recently
Why should investors analyze insider trading activity? Insiders, or people in high positions within a company—such as executives and directors—can have crucial insights into the company’s strategic...
Should You Hold Apellis Pharmaceuticals (APLS)?
PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. Given concerns regarding the decreasing pace of U.S.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Call Transcript November 5, 2024Apellis Pharmaceuticals, Inc. misses on earnings expectations.
Should You Hold Apellis Pharmaceuticals (APLS)?
PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Largest Biotech Hedge Funds and Their Top Stock Picks
The ability to successfully make money through investment requires deep thinking and analysis.
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis Pharmaceuticals Second Quarter 2024 Earnings Conference Call.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.54 EPS, expectations were $-0.54. Apellis Pharmaceuticals, Inc.
Billionaire Hedge Funds
